Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Drug Costs
441 - 460 of 703 Results
-
-
Health Care Industry ‘Pays Tribute’ To California’s Influential Lawmakers
The leaders of California’s legislative health committees who wield power over state health policy have been showered with money from the health care sector, with drug companies, health plans, hospitals and doctors providing nearly 40 percent of their 2017-18 campaign funds.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
-
No Cash, No Heart. Transplant Centers Require Proof Of Payment.
The case of a Michigan woman told to fundraise $10,000 for a heart transplant sparked viral outrage, but experts say “wallet biopsies” are common.
-
Government Investigation Finds Flaws In the FDA’s Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
By Sarah Jane Tribble and Sydney Lupkin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
-
Democrats Winning Key Leadership Jobs Have Taken Millions From Pharma
Top House Republican also received more than $1 million from drugmakers since 2007.
-
Fish Oil Drug Looks Heart-Healthy. Just Don’t Swallow It Hook, Line And Sinker.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.
-
New Congress To Tackle Burning Health Care Issues, Including Drug Prices
KHN’s Sarah Jane Tribble discusses the twists and turns with CBS News.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ Doctors, Guns And Lame Ducks
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
-
House Dems In New Seats Of Power Will Steer Health Policy, Attack Drug Prices
Democrats, who have a history of championing the Affordable Care Act and railing about drug prices, will now chair several house committees.
-
Podcast: KHN’s ‘What The Health?’ Open Enrollment And A Midterm Preview
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week’s midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN “Bill of the Month” feature.
-
Pricey Precision Medicine Often Financially Toxic For Cancer Patients
Medical treatments targeting the DNA in tumor cells are celebrated, but insurers often won’t cover the skyrocketing cost.
By Liz Szabo -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
-
Podcast: KHN’s ‘What The Health?’ Trump, GOP Fight Back On Health Care
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.